CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has fully upheld its Tuschl II ’044 (EP 1407044) patent in oral opposition proceedings held in Munich. Specifically, the originally granted claims of the ’044 patent were upheld without any modification and were deemed valid and supported by the EPO. Opponents included Sirna Therapeutics Inc., a subsidiary of Merck & Co., Silence Therapeutics AG, Pfizer Inc., BASF SE, and an anonymous party, who collectively failed in their arguments during the course of multi-day proceedings to revoke the patent.
